Introduction: This study aimed to evaluate the relationship between pathological and clinical risk classifications in newly diagnosed prostate cancer patients, and 68Ga-PSMA PET/CT data and serum Prostate Specific Antigen (PSA) values. Method: A total of 203 patients who were diagnosed with prostate cancer between 2019 and 2023, who had not yet received treatment and who underwent 68Ga-PSMA PET/CT for staging purposes were included in this study. Results: There was a substantial correlation between D’Amico risk classification, Gleason score, ISUP classification, and the presence or absence of metastasis (p < 0.0001). The median SUVmax value of the prostate gland and the D’Amico risk classification were statistically significantly correlated. (p < 0.0001). There was a statistically significant correlation between the ISUP classification and the PSA value and prostate gland SUVmax value (p < 0.0001). There was a significant correlation between the median SUVmax values of the prostate gland at the time of diagnosis and the patients with and without metastases (p < 0.0001). According to the data obtained from ROC analysis, patients with prostate gland SUVmax values of 8.75 and above were found to have a high probability of metastasis with a sensitivity of 78.9% and a specificity of 59.05%. Conclusion: Our study showed that 68Ga-PSMA PET/CT is a highly effective method for staging newly diagnosed high-risk prostate cancer. The probability of metastasis was found to be dramatically increased in Gleason 8 and above. According to D’Amico risk classification, metastasis was detected in at least half of high-risk patients. Since the sensitivity of metastasis was 78.9% in patients with prostate gland SUVmax value above 8.75, we think that these patients should be carefully reported in terms of metastasis.
Background and Objectives: Neuroendocrine neoplasms are heterogeneous tumours arising from endocrine gland cells and the neuroendocrine system. Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) constitute two-thirds of this tumour group. This study was aimed at investigating the relationship between histone deacetylase enzymes (HDAC) and glutamine synthetase (GS) positivity, and 68Ga-DOTATATE PET/CT data and their effect on prognosis in gastroenteropancreatic neuroendocrine tumours. Materials and Methods: Twenty-seven patients with Grade 1 and Grade 2 well-differentiated neuroendocrine tumours, diagnosed by biopsy and admitted to our nuclear medicine clinic for staging were included in the study. Results: There was no statistically significant correlation between HDAC and GS positivity in tumours and DOTATATE SUVmax value on PET/CT. There was no significant correlation between HDAC and GS positivity or negativity in the tumour and the presence or absence of metastasis on PET/CT. There was no statistically significant relationship between HDAC and GS positivity and survival. There was a statistically significant correlation between DOTATATE SUVmax value on PET/CT and survival (p = 0.039). Conclusions: According to the results of the present study, overall survival rates decreased in patients with high 68Ga-DOTATATE uptake on PET/CT and therefore, patients with high SUVmax on PET/CT should be followed closely and their prognosis may be poor. In addition, although not statistically significant, the mortality rate is higher in patients with HDAC-positive tumours compared to in patients with HDAC-negative tumours; thus, it should be kept in mind that the prognosis of such patients may also be poor. According to the results of the present study, GS levels were generally negative in NETs. In addition, there was no statistically significant relationship between GS levels and survival.